AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8344108 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic sclerotherapy
Number of subjects: 820
Study 8344108 — intervention group
Group type: COMPARATOR
Intervention: Emergency sclerotherapy
Number of subjects: 820
Study 3738655 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine sulphate bolus of 1.5 mg/m2
Number of subjects: 40
Study 3738655 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 40
Study 3738655 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine sulphate
Number of subjects: 40
Study 28629268 — intervention group
Group type: EXPERIMENTAL
Intervention: Cawthorne-Cooksey exercises (n=24)
Number of subjects: 72
Study 28629268 — intervention group
Group type: EXPERIMENTAL
Intervention: Frenkel exercises (n=23)
Number of subjects: 72
Study 28629268 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group, n=25)
Number of subjects: 72
Study 27106972 — intervention group
Group type: EXPERIMENTAL
Intervention: SARI (Simplified Airway Risk Index)
Number of subjects: 64273
Study 27106972 — intervention group
Group type: COMPARATOR
Intervention: Usual airway assessment (Non-SARI)
Number of subjects: 64273
Study 25488080 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized fetal heart rate (FHR) analysis with interactive advice to the operator
Number of subjects: 2869
Study 25488080 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized fetal heart rate (FHR) analysis
Number of subjects: 2869
Study 21871635 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate dispersible tablets (5 mg Zn)
Number of subjects: 451
Study 21871635 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate solution (5 mg Zn/5 mL)
Number of subjects: 451
Study 21871635 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 451
Study 20976374 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin - 200 mg/day (Group Aspirin - GA)
Number of subjects: 229
Study 20976374 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin at individually-adjusted doses (Group Warfarin - GW)
Number of subjects: 229
Study 18545068 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg coadministered with simvastatin 20 mg
Number of subjects: 144
Study 18545068 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 20 mg (monotherapy)
Number of subjects: 144
Study 18545068 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe and simvastatin group
Number of subjects: 144
Study 18545068 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin monotherapy group
Number of subjects: 144
Study 18545068 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe coadministered with simvastatin
Number of subjects: 144
Study 11329544 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm Stabilizing Algorithm (RSA) during baseline AF (pacer set to default V/VI 50/min)
Number of subjects: 11
Study 11329544 — intervention group
Group type: EXPERIMENTAL
Intervention: Low clinically indicated pacing rate (69+/‐9 beats/min) after ablation
Number of subjects: 11
Study 11329544 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid regular pacing at mean preablation rate (110+/‐18 beats/min) after ablation
Number of subjects: 11
Study 9758072 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic Arnica 30x
Number of subjects: 519
Study 9758072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 519
Study 7930468 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (10 mg bid)
Number of subjects: 36
Study 7930468 — intervention group
Group type: COMPARATOR
Intervention: Non-treated (Control)
Number of subjects: 36
Study 3339948 — intervention group
Group type: EXPERIMENTAL
Intervention: Veralipride (200 mg/day for 20 days) + Naloxone (1.6 mg/h for 4 h)
Number of subjects: 0
Study 3339948 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 0
Study 3339948 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone infusion
Number of subjects: 0
Study 31205195 — intervention group
Group type: EXPERIMENTAL
Intervention: Asenapine (10-20 mg/d)
Number of subjects: 120
Study 31205195 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine (10-20 mg/d)
Number of subjects: 120
Study 28161384 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose control (BG 100‐140mg/dl [5.5‐7.8mM])
Number of subjects: 288
Study 28161384 — intervention group
Group type: COMPARATOR
Intervention: Conservative glucose control (BG 141‐180mg/dl [7.9‐10.0mM])
Number of subjects: 288
Study 26236676 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised tooth brushing under the supervision of parents (Group A)
Number of subjects: 315
Study 26236676 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised tooth brushing under the supervision of a caregiver (Group B)
Number of subjects: 315
Study 26236676 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised tooth brushing under the supervision of both investigator and caregiver (Group C)
Number of subjects: 315
Study 24280442 — intervention group
Group type: EXPERIMENTAL
Intervention: Huai Qi Huang (HQH)
Number of subjects: 45
Study 24280442 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 45
Study 21623250 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance base-out (BO) break
Number of subjects: 114
Study 21623250 — intervention group
Group type: EXPERIMENTAL
Intervention: Near base-out (BO) break
Number of subjects: 114
Study 21623250 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance base-in (BI) break
Number of subjects: 114
Study 21623250 — intervention group
Group type: EXPERIMENTAL
Intervention: Near base-in (BI) break
Number of subjects: 114
Study 21623250 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance phoria
Number of subjects: 114
Study 21623250 — intervention group
Group type: EXPERIMENTAL
Intervention: Near phoria
Number of subjects: 114
Study 21623250 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance interpupillary distance (IPD)
Number of subjects: 114
Study 18441705 — intervention group
Group type: EXPERIMENTAL
Intervention: Coraxan
Number of subjects: 95
Study 18441705 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 95
Study 16585867 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative accelerated hyperfractionated radiotherapy with concurrent cisplatin followed immediately by surgery and intraoperative radiotherapy, completed with early postoperative weekly paclitaxel, two additional cisplatin cycles, and concurrent once‐daily radiotherapy beginning on day 28 after surgery
Number of subjects: 43
Study 12897503 — intervention group
Group type: EXPERIMENTAL
Intervention: Color Doppler Ultrasonography
Number of subjects: 36
Study 12897503 — intervention group
Group type: COMPARATOR
Intervention: Control group (16 individuals without spine deformity)
Number of subjects: 36
Study 10845965 — intervention group
Group type: EXPERIMENTAL
Intervention: Trim and fill fixed effects analysis method
Number of subjects: 48
Study 10845965 — intervention group
Group type: EXPERIMENTAL
Intervention: Random effects model
Number of subjects: 48
Study 10845965 — intervention group
Group type: EXPERIMENTAL
Intervention: Publication bias adjustment
Number of subjects: 48
Study 9148534 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Expiratory Pressure (PEP)
Number of subjects: 66
Study 9148534 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Resistance-Positive Expiratory Pressure (IR-PEP)
Number of subjects: 66
Study 9148534 — intervention group
Group type: COMPARATOR
Intervention: Routine chest physiotherapy alone
Number of subjects: 66
Study 10779311 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocabastine eye-drops
Number of subjects: 17
Study 10779311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 31494289 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of a brachial plexus biological dose constraint in IMPT plans (cohort B).
Number of subjects: 51
Study 31494289 — intervention group
Group type: COMPARATOR
Intervention: IMPT plans without BP biological dose constraint (cohort A).
Number of subjects: 51
Study 31494289 — intervention group
Group type: EXPERIMENTAL
Intervention: MCBD plans (cohort B).
Number of subjects: 51
Study 31494289 — intervention group
Group type: COMPARATOR
Intervention: Eclipse plans (cohort B).
Number of subjects: 51
Study 29258851 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic granular calcium phosphate compound (CPC)
Number of subjects: 18
Study 29258851 — intervention group
Group type: COMPARATOR
Intervention: Bovine mineral
Number of subjects: 18
Study 29258851 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite bisphosphonate‐linked hyaluronic acid‐calcium phosphate hydrogel (HABP·CaP)
Number of subjects: 18
Study 26767377 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RT)
Number of subjects: 287
Study 26767377 — intervention group
Group type: COMPARATOR
Intervention: Non-training controls
Number of subjects: 287
Study 24723582 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan-based treatment
Number of subjects: 939
Study 24723582 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol-based treatment
Number of subjects: 939
Study 24723582 — intervention group
Group type: COMPARATOR
Intervention: Normal LVM
Number of subjects: 939
Study 23006960 — intervention group
Group type: EXPERIMENTAL
Intervention: BIA guided fluid management (BCM measurements every 2 months)
Number of subjects: 1300
Study 23006960 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control arm)
Number of subjects: 1300
Study 23006960 — intervention group
Group type: EXPERIMENTAL
Intervention: BIA guided fluid management
Number of subjects: 1300
Study 20418695 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine
Number of subjects: 120
Study 20418695 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.50% ropivacaine
Number of subjects: 120
Study 20418695 — intervention group
Group type: COMPARATOR
Intervention: saline (Group S)
Number of subjects: 120
Study 20418695 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% ropivacaine
Number of subjects: 120
Study 17904420 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal CPAP
Number of subjects: 60
Study 17904420 — intervention group
Group type: COMPARATOR
Intervention: Sham-CPAP
Number of subjects: 60
Study 17904420 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal CPAP (in patients with obstructive sleep apnea)
Number of subjects: 60
Study 17904420 — intervention group
Group type: COMPARATOR
Intervention: Sham-CPAP (in patients with obstructive sleep apnea)
Number of subjects: 60
Study 16622086 — intervention group
Group type: COMPARATOR
Intervention: T-Gel 0.1% MD (multidose)
Number of subjects: 175
Study 16622086 — intervention group
Group type: EXPERIMENTAL
Intervention: T-Gel 0.1% SDU (single dose unit)
Number of subjects: 175
Study 16622086 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (T-Gel 0.1% MD and T-Gel 0.1% SDU)
Number of subjects: 175
Study 12793022 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic uterine nerve ablation
Number of subjects: 24
Study 12793022 — intervention group
Group type: EXPERIMENTAL
Intervention: Presacral neurectomy
Number of subjects: 24
Study 11379470 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate (DMPA)
Number of subjects: 19
Study 8800102 — intervention group
Group type: EXPERIMENTAL
Intervention: Precordial ST segment depression (in leads V1 to V3, V4 to V6, or both)
Number of subjects: 16521
Study 8800102 — intervention group
Group type: COMPARATOR
Intervention: No precordial ST segment depression
Number of subjects: 16521
Study 8800102 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnitude of precordial ST segment depression
Number of subjects: 16521
Study 1320521 — intervention group
Group type: EXPERIMENTAL
Intervention: sodium valproate
Number of subjects: 228
Study 1320521 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 228
Study 6529776 — intervention group
Group type: EXPERIMENTAL
Intervention: Terconazole (R-42470) cream 0.4%
Number of subjects: 78
Study 6529776 — intervention group
Group type: COMPARATOR
Intervention: Clotrimazole cream 1%
Number of subjects: 78
Study 31450520 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy (OT), Nordic walking (NW), and therapeutic touch (TT)
Number of subjects: 17
Study 30400858 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension awareness
Number of subjects: 4485
Study 30400858 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension treatment
Number of subjects: 4485
Study 30400858 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure control
Number of subjects: 4485
Study 30400858 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of hypertension
Number of subjects: 4485
Study 25060395 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocker outsole shoe (with a toe‐only rocker sole)
Number of subjects: 17
Study 25060395 — intervention group
Group type: COMPARATOR
Intervention: Baseline shoe (without a rocker outsole)
Number of subjects: 17
Study 25715484 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir 800/100 mg
Number of subjects: 0
Study 25715484 — intervention group
Group type: COMPARATOR
Intervention: Atazanavir/ritonavir
Number of subjects: 0
Study 23110478 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Negative Pressure (TNP) with dermal substitute
Number of subjects: 86
Study 23110478 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Negative Pressure (TNP) without dermal substitute
Number of subjects: 86
Study 23110478 — intervention group
Group type: COMPARATOR
Intervention: Dermal substitute without TNP
Number of subjects: 86
Study 23110478 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dermal substitute, no TNP)
Number of subjects: 86
Study 20213205 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care office-based buprenorphine/naloxone treatment (dosage and duration not specified)
Number of subjects: 166
Study 17541206 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs) for approximately 12 weeks
Number of subjects: 25
Study 17541206 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 25
Study 15738287 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD patients (ex-smokers and continuing smokers)
Number of subjects: 0
Study 15738287 — intervention group
Group type: COMPARATOR
Intervention: Nonsmoking controls
Number of subjects: 0
Study 11825814 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine, 0.2%, twice a day
Number of subjects: 115
Study 11825814 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost, 0.005%, every day
Number of subjects: 115
Study 11825814 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost
Number of subjects: 115
Study 9585684 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal binder and electrical stimulation
Number of subjects: 24
Study 9585684 — intervention group
Group type: COMPARATOR
Intervention: Abdominal binder
Number of subjects: 24
Study 9585684 — intervention group
Group type: COMPARATOR
Intervention: Voluntary coughing
Number of subjects: 24
Study 7649149 — intervention group
Group type: EXPERIMENTAL
Intervention: Running (R)
Number of subjects: 30
Study 7649149 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-training (XT)
Number of subjects: 30
Study 7649149 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 30
Study 2651758 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,25(OH)2D3 at a dose of 0.25 to 0.5 microgram daily
Number of subjects: 16
Study 2651758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 610977 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 12
Study 610977 — intervention group
Group type: COMPARATOR
Intervention: Placebo-acupuncture
Number of subjects: 12
Study 610977 — intervention group
Group type: COMPARATOR
Intervention: Atrovent (parasympatholytic drug)
Number of subjects: 12
Study 27834264 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided disclosure protocol (3 sessions of 20 minutes each)
Number of subjects: 0
Study 27834264 — intervention group
Group type: COMPARATOR
Intervention: Active control condition (3 sessions of 20 minutes each)
Number of subjects: 0
Study 28804985 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Cue Exposure Therapy (CET)
Number of subjects: 64
Study 28804985 — intervention group
Group type: COMPARATOR
Intervention: A-CBT
Number of subjects: 64
Study 25921095 — intervention group
Group type: EXPERIMENTAL
Intervention: General quadriceps exercise
Number of subjects: 50
Study 25921095 — intervention group
Group type: COMPARATOR
Intervention: Specific-VM exercise
Number of subjects: 50
Study 22505251 — intervention group
Group type: EXPERIMENTAL
Intervention: sTWEAK levels
Number of subjects: 131
Study 22505251 — intervention group
Group type: EXPERIMENTAL
Intervention: sTWEAK levels in patients with severe vascular calcification (CACs ≥400)
Number of subjects: 131
Study 21829501 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body cryotherapy (WBC) for 96 h post-exercise, repeated each day
Number of subjects: 11
Study 21829501 — intervention group
Group type: COMPARATOR
Intervention: Passive recovery (PAS)
Number of subjects: 11
Study 19203988 — intervention group
Group type: COMPARATOR
Intervention: Lactobacillus rhamnosus 35 (Lcr35) 0 CFU/day (Control group)
Number of subjects: 23
Study 19203988 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus 2 x 10(8) CFU/day (Low-dose group)
Number of subjects: 23
Study 19203988 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus 6 x 10(8) CFU/day (High-dose group)
Number of subjects: 23
Study 16758382 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin/Tazobactam 4.5 g
Number of subjects: 300
Study 16758382 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin 4 g
Number of subjects: 300
Study 16758382 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin
Number of subjects: 300
Study 16758382 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin/Tazobactam
Number of subjects: 300
Study 16758382 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin and Piperacillin/Tazobactam
Number of subjects: 300
Study 14561107 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (NTX)
Number of subjects: 0
Study 10988100 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (400 microgram, twice daily)
Number of subjects: 14
Study 10988100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 8792357 — intervention group
Group type: EXPERIMENTAL
Intervention: Lodoxamide 0.1% eye drops
Number of subjects: 120
Study 8792357 — intervention group
Group type: COMPARATOR
Intervention: N-acetyl aspartyl glutamic acid 6% (NAAGA) drops
Number of subjects: 120
Study 1610573 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced-air warmer (43 degrees C, blanket covering legs)
Number of subjects: 20
Study 1610573 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating-water blanket (40 degrees C)
Number of subjects: 20
Study 1610573 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated humidifier (40 degrees C)
Number of subjects: 20
Study 1610573 — intervention group
Group type: COMPARATOR
Intervention: Control (no extra warming)
Number of subjects: 20
Study 6531660 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg
Number of subjects: 0
Study 6531660 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg
Number of subjects: 0
Study 6531660 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 80 mg (initial loading dose)
Number of subjects: 0
Study 6531660 — intervention group
Group type: COMPARATOR
Intervention: Histamine H2-receptor antagonists (high doses)
Number of subjects: 0
Study 31498177 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide oral suspension (BOS) 2.0 mg twice daily
Number of subjects: 0
Study 31498177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30650617 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable non-invasive ventilation (pNIV) during recovery
Number of subjects: 24
Study 30650617 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable non-invasive ventilation (pNIV) after 12 weeks
Number of subjects: 24
Study 25387324 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Recovery (AR)
Number of subjects: 32
Study 25387324 — intervention group
Group type: COMPARATOR
Intervention: Passive Recovery (PR)
Number of subjects: 32
Study 25387324 — intervention group
Group type: EXPERIMENTAL
Intervention: End-exercise Blood Lactate (La)
Number of subjects: 32
Study 25387324 — intervention group
Group type: EXPERIMENTAL
Intervention: End-exercise Blood pH
Number of subjects: 32
Study 22974968 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 min of morning exercise at 60% VO(2peak)
Number of subjects: 0
Study 22974968 — intervention group
Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 0
Study 22102856 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHA-PPQ)
Number of subjects: 474
Study 22102856 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AM-LM)
Number of subjects: 474
Study 17964785 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall Neuropathy Limitations Scale (ONLS)
Number of subjects: 40
Study 17964785 — intervention group
Group type: EXPERIMENTAL
Intervention: 10‐m timed walk (T10MW)
Number of subjects: 40
Study 17964785 — intervention group
Group type: EXPERIMENTAL
Intervention: 9‐hole‐peg test (9‐HPT)
Number of subjects: 40
Study 17964785 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal voluntary isometric contraction (MVIC) of arm (elbow flexion, hand‐grip, and three‐point pinch)
Number of subjects: 40
Study 17964785 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal voluntary isometric contraction (MVIC) of leg (knee extension, foot dorsiflexion/plantar flexion)
Number of subjects: 40
Study 17964785 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot dorsiflexion using an immobilization device
Number of subjects: 40
Study 17964785 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot plantar flexion using an immobilization device
Number of subjects: 40
Study 16571960 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 4.0 mg/kg
Number of subjects: 27